New landmark nature study provides long-sought mechanistic link between ebv and multiple sclerosis, extending findings from recent paper in science that identified ebv as the leading cause of multiple sclerosis

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today lauded the second high impact study this month solidifying ebv as the primary driver of the development of ms. the paper, titled, “clonally expanded b cells in multiple sclerosis bind ebv ebna1 and glialcam,” w
ATRA Ratings Summary
ATRA Quant Ranking